Collegium Pharmaceutical
COLL
138 hedge funds and large institutions have $745M invested in Collegium Pharmaceutical in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 40 increasing their positions, 54 reducing their positions, and 22 closing their positions.
9% more call options, than puts
Call options by funds: $1.85M | Put options by funds: $1.7M
0.31% more ownership
Funds ownership: 107.18% → 107.49% (+0.31%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less capital invested
Capital invested by funds: $770M → $745M (-$25.6M)
9% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 22
1% less funds holding
Funds holding: 140 → 138 (-2)
26% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$8.23M |
| 2 |
Principal Financial Group
Des Moines,
Iowa
|
+$7.31M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$4.66M |
| 4 |
Millennium Management
New York
|
+$3.21M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$2.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$8.43M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$8.02M |
| 3 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$3.66M |
| 4 |
FA
Friess Associates
Greenville,
Delaware
|
-$2.78M |
| 5 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
-$2.35M |
COLL Hedge Fund Activity: Q4 2020 in Review
138 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q4 2020, worth a combined $745M — down 3.3% from $770M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of COLL and 20 opened new positions — a net loss of 2 holders — while 54 trimmed existing stakes and 40 added.
The largest buyer was Great Point Partners, opening a new position worth an estimated $8.23M. The largest seller was Mangrove Partners, cutting an estimated $8.43M.
- 138 institutional investors held Collegium Pharmaceutical (COLL) as of Q4 2020, down from 140 in Q3 2020.
- Funds reported $745M of Collegium Pharmaceutical stock for Q4 2020, down 3.3% quarter-over-quarter.
- 20 funds opened new Collegium Pharmaceutical positions in Q4 2020 and 22 closed out, a net change of -2 holders.
- The largest Collegium Pharmaceutical buyer in Q4 2020 was Great Point Partners, an estimated $8.23M added.
- The largest Collegium Pharmaceutical seller in Q4 2020 was Mangrove Partners, an estimated $8.43M sold.
Based on aggregated 13F filings for Q4 2020.